At this year’s annual meeting of the American Society of Hematology (ASH), Johnson & Johnson (NYSE: JNJ) has impressed with the first clinical data from its anti-BCMA CAR-T program, as rival candidates jostle for the lead in this area of innovation.
J&J presented data from the Phase Ib/II CARTITUDE-1 study of JNJ-4528 in people with relapsed or refractory multiple myeloma.
The heavily pre-treated patients in the test showed early and deep responses, with 100% showing a response at a median follow-up of six months. The overall response rate (ORR) included 69% of patients achieving a complete response (CR) or better.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze